Mutant interleukin-2 (IL-2) polypeptides
US8906356B2 · kind B2 · utility
18Cited by
6References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 5, 2008 |
| Grant date | Dec 9, 2014 |
| Priority date | — |
| Expiry date | Nov 26, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to mutant IL-2 polypeptides that act as receptor antagonists. The mutant IL-2 polypeptides bind CD 25 but do not activate the IL-2 receptor. Also provided are methods of using the mutant IL-2 polypeptides, for example, to treat a patient who has cancer or a viral infection. The mutant polypeptides can also be used in various delivery systems.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.